A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...
The deal, which involves up to 8 “next-generation” weight loss medications and could be worth more than $18 billion, ranks as ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results